The content on this site is intended for healthcare professionals only
Dr Raez speaks with ecancertv at the Best of ASCO 2016 about developments in immunotherapy to treat lung cancer.
He describes the improved patient outcomes resulting from combined immunotherapy treatment, and how to cope with associated toxicities.
Dr Raez also highlights the potential of CAR-T cell therapy to treat lung cancer.
Combined courses of ipilimumab and nivolumab have been approved in the UK to treat melanoma, and it was recently reported that PD-L1 selection improved cost effectiveness of nivolumab as a single agent against NSCLC.
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Uncommon genetic aberrations NTRK, RET, NRG
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Choosing Wisely in radiology Tanzania
